Aftovaxpur DOE

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Največ tri od naslednjih prečiščeni, inaktivirano slinavke in parkljevke virus sevov: O1 Manisa ≥ 6 PD50*; O1 BFS ≥ 6 PD50*; O Tajvanu, 3/97 ≥ 6 PD50*; A22 Iraku ≥ 6 PD50*; A24 Cruzeiro ≥ 6 PD50*; Puranji 14/98 ≥ 6 PD50*; Azija 1 Shamir ≥ 6 PD50*; SAT2 Savdska Arabija ≥ 6 PD50*; * PD50 – 50% zaščitni odmerek goveda, kot je opisano v doktor tehniških znanosti Eur. monografija 0063.

Available from:

Boehringer Ingelheim Vetmedica GmbH

ATC code:

QI02AA04

INN (International Name):

inactivated vaccine against foot-and-mouth disease

Therapeutic group:

Pigs; Cattle; Sheep

Therapeutic area:

Imunologija

Therapeutic indications:

Aktivna imunizacija goveda, ovac in prašičev od 2 tedna starosti proti slinavki in parkljevki za zmanjšanje kliničnih znakov.

Product summary:

Revision: 8

Authorization status:

Umaknjeno

Authorization date:

2013-07-15

Patient Information leaflet

                                17
B. NAVODILO ZA UPORABO
Zdravilo nima veā dovoljenja za promet
18
NAVODILO ZA UPORABO:
AFTOVAXPUR DOE emulzija za injiciranje za govedo, ovce in prašiče
1.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER
PROIZVAJALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ, ČE STA
RAZLIČNA
Imetnik dovoljenja za promet z zdravilom:
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
NEMČIJA
Proizvajalec, odgovoren za sproščanje serij:
Boehringer Ingelheim Animal Health France SCS
Laboratoire Porte des Alpes
Rue de l’Aviation
69800 Saint Priest
Francija
2.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
AFTOVAXPUR DOE emulzija za injiciranje za govedo ovce in prašiče
3.
NAVEDBA UČINKOVIN(E) IN DRUGIH SESTAVIN
Vsak odmerek (2 ml) emulzije vsebuje:
UČINKOVINA:
Prečiščeni, inaktivirani antigeni virusa slinavke in parkljevke,
vsaj 6 ZO
50
* na sev
*ZO
50
– 50% zaščitnega odmerka pri govedu, pri govedu, kot določa Ph.
Eur monografija 0063.
Število in tip sevov, vključenih v končno zdravilo, bosta
prilagojena trenutni epidemiološki situaciji v
času formulacije končnega zdravila in bosta označena na ovojnini.
DODATEK:
Tekoči parafin 537 mg.
Bela emulzija po pretresanju.
4.
INDIKACIJA(E)
Aktivna imunizacija goveda, ovc in prašičev od 2 tednov starosti
proti slinavki in parkljevki za
zmanjšanje pojavnosti kliničnih znakov.
Nastop imunosti:
Govedo in ovce: 7 dni po cepljenju.
Prašiči: 4 tedne po cepljenju.
Zdravilo nima veā dovoljenja za promet
19
Trajanje imunosti: cepljenje goveda, ovc in prašičev inducira
nastanek nevtralizacijskih protiteles, ki
vztrajajo vsaj 6 mesecev. Pri govedu so izmerjene vrednosti protiteles
nad tistimi, ki dokazano
zaščitijo živali.
5.
KONTRAINDIKACIJE
Jih ni.
6.
NEŽELENI UČINKI
Oteklina (premera do 12 cm pri prežvekovalcih in 4 cm pri prašičih)
se je po cepljenju z enim
odmerkom cepiva zelo pogosto pojavila pri večini živali. Te lokalne
reakcije običajno izginejo v
4 tednih po cepljenju, lahko pa pri majhnem številu živali vztrajajo
dlje.

                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
Zdravilo nima veā dovoljenja za promet
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 04-07-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 04-07-2023
Public Assessment Report Public Assessment Report Bulgarian 13-06-2016
Patient Information leaflet Patient Information leaflet Spanish 04-07-2023
Public Assessment Report Public Assessment Report Spanish 04-07-2023
Patient Information leaflet Patient Information leaflet Czech 04-07-2023
Public Assessment Report Public Assessment Report Czech 13-06-2016
Patient Information leaflet Patient Information leaflet Danish 04-07-2023
Public Assessment Report Public Assessment Report Danish 13-06-2016
Patient Information leaflet Patient Information leaflet German 04-07-2023
Public Assessment Report Public Assessment Report German 13-06-2016
Patient Information leaflet Patient Information leaflet Estonian 04-07-2023
Public Assessment Report Public Assessment Report Estonian 04-07-2023
Patient Information leaflet Patient Information leaflet Greek 04-07-2023
Public Assessment Report Public Assessment Report Greek 13-06-2016
Patient Information leaflet Patient Information leaflet English 04-07-2023
Public Assessment Report Public Assessment Report English 04-07-2023
Patient Information leaflet Patient Information leaflet French 04-07-2023
Public Assessment Report Public Assessment Report French 04-07-2023
Patient Information leaflet Patient Information leaflet Italian 04-07-2023
Public Assessment Report Public Assessment Report Italian 04-07-2023
Patient Information leaflet Patient Information leaflet Latvian 04-07-2023
Public Assessment Report Public Assessment Report Latvian 04-07-2023
Patient Information leaflet Patient Information leaflet Lithuanian 04-07-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 04-07-2023
Public Assessment Report Public Assessment Report Lithuanian 04-07-2023
Patient Information leaflet Patient Information leaflet Hungarian 04-07-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 04-07-2023
Public Assessment Report Public Assessment Report Hungarian 04-07-2023
Patient Information leaflet Patient Information leaflet Maltese 04-07-2023
Public Assessment Report Public Assessment Report Maltese 04-07-2023
Patient Information leaflet Patient Information leaflet Dutch 04-07-2023
Public Assessment Report Public Assessment Report Dutch 04-07-2023
Patient Information leaflet Patient Information leaflet Polish 04-07-2023
Public Assessment Report Public Assessment Report Polish 04-07-2023
Patient Information leaflet Patient Information leaflet Portuguese 04-07-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 04-07-2023
Public Assessment Report Public Assessment Report Portuguese 04-07-2023
Patient Information leaflet Patient Information leaflet Romanian 04-07-2023
Public Assessment Report Public Assessment Report Romanian 04-07-2023
Patient Information leaflet Patient Information leaflet Slovak 04-07-2023
Public Assessment Report Public Assessment Report Slovak 04-07-2023
Patient Information leaflet Patient Information leaflet Finnish 04-07-2023
Public Assessment Report Public Assessment Report Finnish 04-07-2023
Patient Information leaflet Patient Information leaflet Swedish 04-07-2023
Public Assessment Report Public Assessment Report Swedish 04-07-2023
Patient Information leaflet Patient Information leaflet Norwegian 04-07-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 04-07-2023
Patient Information leaflet Patient Information leaflet Icelandic 04-07-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 04-07-2023
Patient Information leaflet Patient Information leaflet Croatian 04-07-2023
Public Assessment Report Public Assessment Report Croatian 04-07-2023

View documents history